FDA Extends Drug Safety Advisory Committee
Published Date: 5/26/2026
Notice
Summary
The FDA is renewing its Drug Safety and Risk Management Advisory Committee for two more years, keeping it active until May 31, 2028. This committee helps the FDA make smart decisions about drug safety and risks, protecting everyone who uses medicines. No new costs or big changes, just a continued commitment to keeping drugs safe and sound.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Opioid Safety Labeling Required
Following a May 5, 2025 advisory meeting, FDA required safety labeling changes to all opioid pain medications and sent letters to applicants giving companies 30 days to submit labeling updates for review. These labeling changes explain clearer risks and dosing warnings to help patients and clinicians make safer decisions.
Clozapine REMS Burden Reduced
As of February 24, 2025, FDA no longer expects prescribers, pharmacies, and patients to participate in the REMS program for clozapine or to report absolute neutrophil count (ANC) blood tests before pharmacies dispense clozapine. FDA continues to recommend that prescribers monitor ANC according to the prescribing information.
iPLEDGE REMS Changes for Isotretinoin
On February 9, 2026, FDA approved significant modifications to the iPLEDGE REMS for isotretinoin; the changes—effective August 8, 2026—include allowing at-home pregnancy tests, removing the 19-day lockout/waiting period, and reducing documentation requirements for patient counseling.
FDA Drug Safety Committee Renewed
The FDA renewed the Drug Safety and Risk Management Advisory Committee for two more years so the committee will remain active through May 31, 2028. You will still have this advisory group reviewing drug safety, risk management, and risk communication for FDA-regulated medicines during that period.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-10369, Self-Regulatory Organizations; NYSE Arca, Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Delete the Cabinet Upgrade Fee
NYSE Arca is scrapping the $9,200 cabinet upgrade fee for users who want more power in their dedicated cabinets. This change means traders and firms using these cabinets will save money starting immediately. No more surprise charges for power boosts—just smoother, cheaper access to the Exchange’s tech setup!
Next: 2026-10372, Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
The FDA wants your thoughts on how they collect info about making custom human drugs under special rules (Sections 503A and 503B). This affects pharmacies and drug makers who mix medicines just for patients. You’ve got until July 27, 2026, to share your comments—no cost changes yet, just a chance to help shape the paperwork process!